|
1) Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006; 43: S173-81
|
|
|
|
2) Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006; 26: 130-41
|
|
|
|
|
|
3) Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006; 4: 936-62
|
|
|
|
|
|
4) Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007; 45: 1056-75
|
|
|
|
|
|
5) Lok AS, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B. Hepatology. 2007; 45: 507-39
|
|
|
|
|
|
6) Lok AS, Zoulim F, Locarnini S. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46: 254-65
|
|
|
|
|
|
7) Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005; 128: 1890-7
|
|
|
|
|
|
8) Wong DK, Yuen MF, Ngai VW, et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006; 11: 909-16
|
|
|
|
|
|
9) Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354: 1001-10
|
|
|
|
|
|
10) Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354: 1011-20
|
|
|
|
|
|
11) Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007; 81: 3992-4001
|
|
|
|
|
|
12) Lai CL, Leung N, Teo EK. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129: 528-36
|
|
|
|
|
|
13) Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-95
|
|
|
|
|
|
14) Flink HJ, Hansen BE, Heathcote EL, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006; 101: 2523-9
|
|
|
|
|
|
15) Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007; 46: 388-94
|
|
|
|
|
|
16) Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365: 123-9
|
|
|
|
|
|
17) Sypsa VA, Mimidis K, Tassopoulos NC, et al, A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. Hepatology. 2005; 42: 77-85
|
|
|
|
|
|
18) Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351: 1206-17
|
|
|
|
|
|
19) van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. HBV 99-01 Study Group. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006; 26: 399-405
|
|
|
|
|
|
20) Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006; 44: 675-84
|
|
|
|
|
|
21) Hatakeyama T, Noguchi C, Hiraga N, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology. 2007; 45: 1179-86
|
|
|
|
|
|
22) Tanaka E, Matsumoto A, Suzuki F, et al. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int. 2006; 26: 90-6
|
|
|
|
|
|
23) Horiike N, Duong TN, Michitaka K, et al. Characteristics of lamivdine-resistant hepatitis B virus (HBV) strains with and without breakthrough hepatitis in patients with chronic hepatitis B evaluated by serial HBV full-genome sequences. J Med Virol. 2007; 79: 911-8
|
|
|
|
|
|
24) Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006; 44: 1656-65
|
|
|
|
|
|
25) Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistence in patients with lamibudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006; 43: 1385-91
|
|
|
|
|
|
26) Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007; 45: 307-13
|
|
|
|
|
|
27) Buti M, Elefsiniotis I, Jardi R, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol. 2007; 47: 366-72
|
|
|
|
|
|
28) van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006; 44: 318-25
|
|
|
|
|
|
29) Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006; 354: 1807-12
|
|
|
|
|
|
30) Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006; 44: 703-12
|
|
|
|
|
|
31) Perrillo RP. Therapy of hepatitis B-viral suppression or eradication. Hepatology. 2006; 43: S182-93
|
|
|
|
|
|
32) Flink HJ, van Zonneveld M, Hansen BE, et al. HBV 99-01 Study Group. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006; 101: 297-303
|
|
|
|
|
|
33) Westland C, Delaney W, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology. 2003; 125: 107-16
|
|
|
|
|
|
34) Moskovitz DN, Osiowy C, Giles E, et al. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat. 2005; 12: 398-404
|
|
|
|
|
|
35) Zollner B, Petersen J, Puchhammer-Stockl E, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology. 2004; 39: 42-50
|
|
|
|
|
|
36) Ramos B, Nunez M, Martin-Carbonero L, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr. 2007; 44: 557-61
|
|
|
|
|
|
37) Palumbo E. Hepatitis B genotypes and response to antiviral therapy: a review. Am J Ther. 2007; 14: 306-9
|
|
|
|
|
|
38) Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006; 44: 1110-6
|
|
|
|
|
|
39) Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study. J Hepatol. 2005; 43: 60-6
|
|
|
|
|
|
40) Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006; 166: 49-56
|
|
|
|
|
|
41) Lee HS, Chung YH, Lee K, et al. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2006; 43: 982-8
|
|
|
|
|
|
42) Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week cievudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007; 45: 1172-8
|
|
|
|
|
|
43) Horiike N, Fazle Akbar SM, Michitaka K, et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol. 2005; 32: 156-61
|
|
|
|
|
|
44) Sung JJ, Lik-Yuen H. HBV-ISS (Dynavax). Curr Opin Mol Ther. 2006; 8: 150-5
|
|
|
|
|
|
45) Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr Opin Investig Drugs. 2007; 8: 125-9
|
|
|
|
|
|
46) Ying C, Li Y, Leung CH, et al. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA. 2007; 104: 8526-31
|
|
|
|
|
|
47) Li GQ, Gu HX, Li D, et al. Inhibition of hepatitis B virus cccDNA replication by siRNA. Biochem Biophys Res Commun. 2007; 355: 404-8
|
|
|
|
|
|
48) Akbar SM, Horiike N, Onji M. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection. World J Gastroenterol. 2006; 12: 2876-83
|
|
|
|
|
|
49) Fazle Akbar SM, Furukawa S, Yoshida S, et al. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J Hepatol. 2007; 47: 60-6
|
|
|
|
|